Coronary artery calcium (CAC) score? (further testing beyond basic labs) Not measured
cac-unknownNo one has reached this rule yetOffered when the decision is still open (borderline or intermediate risk, men ≥40 / women ≥45, or below 3% with a major enhancer)
No clinician has signed off this rule yet. It reflects our reading of the guidelines cited below, which has not been independently checked.
Word for word, as generated for the example person below. Figures in the text are theirs.
A coronary calcium scan — ordered as "CT calcium scoring, heart, without contrast" — would resolve this.
Expert guidelinesOfficial guidelines recommend it, based on trials plus expert judgment.
Your risk sits in the band where the decision is genuinely open, which is what this scan is for. Once you have a number it also sets the target: any calcium supports an LDL goal of 100, a score of 100 or more supports 70, and above 300 a goal of 55 is an option.
ACC/AHA (US)
Graded for adults at intermediate risk and selected adults at borderline risk when the decision about a statin is uncertain. Below 3% risk the guideline does not grade a scan.
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia · Recommendation behind this rule · class and level read from the guideline tables on 2026-09-30
ESC (Europe)
Subclinical atherosclerosis or a raised calcium score should be considered as a risk modifier near a treatment threshold. The ESC sorts risk with SCORE2, not the PREVENT equations used here, so the tiers line up only roughly.
2025 ESC/EAS focused update on dyslipidaemias · Recommendation tables · class and level read from the guideline tables on 2026-09-30
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia · Class 1 · Level B-R
“Borderline risk + high Lp(a)” — an illustrative profile, not a real user.
Asked after: Chronic kidney disease, age 40–75, HIV, age 40–75, 10-year risk 5% to under 10%, 10-year risk 3% to under 5%, Low 10-year risk, high lifetime risk, Low risk with a major risk enhancer
Cited by the recommendations above.
A trial that could change this, still running or reported too recently to be settled.
For practising clinicians. Endorse it, propose a change, or dispute it. We verify every reviewer before a review is shown, and a review stays attached to the version of the rule you saw — if the rule changes, the page says so. You'll be asked to declare any relevant interests; they're shown with your review.
Log in or create an account to submit a review. An account is how we tie a review to a person we can verify.
Runs in lib/engine/lipidPathway.ts as cac-unknown.